Afinitor second line for endometrial cancer – pro
There remains a great neeed for effective second line therapies for recurrent endometrial cancer. Trials of cytotoxic therapies used in the second-line setting have generally produced RRs of 15% or lower, and no newer targeted agents have been approved for treatment of endometrial cancer. NExGEn sequencing results are not yet generally accepted as a sufficient basis for therapy and were not provided to determine the basis for its findings. Personalized Medicine approaches of this type require more study and have not been adopted by guidelines.
Afinitor has some support for recurrent or progressing endometrial cancer. A small study found that patients with endometriod histology and CTNNB1 mutations responded well to everolimus and letrozole. This was a two-institution phase II trial of everolimus and letrozole in women with recurrent EC.
Fleming GF, Second-Line Therapy for Endometrial Cancer: The Need for Better Options. J Clin Oncol. 2015 Nov 1;33(31):3535-40.
M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, K. R. Adler, K. H. Lu, R. L. Coleman; Atlantic Health, Morristown, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX, A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 29: 2011 (suppl; abstr 5012)
NCCN, Uterine Cancer, 2016